Your browser is no longer supported. Please, upgrade your browser.
Settings
MYOK MyoKardia, Inc. daily Stock Chart
MYOK [NASD]
MyoKardia, Inc.
Index- P/E- EPS (ttm)-1.41 Insider Own1.80% Shs Outstand36.21M Perf Week1.93%
Market Cap1.81B Forward P/E- EPS next Y-2.46 Insider Trans-72.16% Shs Float30.51M Perf Month-1.86%
Income-46.00M PEG- EPS next Q-0.29 Inst Own85.20% Short Float6.79% Perf Quarter-7.31%
Sales22.50M P/S80.55 EPS this Y-192.40% Inst Trans0.28% Short Ratio5.60 Perf Half Y32.23%
Book/sh6.81 P/B7.35 EPS next Y-65.10% ROA-19.90% Target Price72.20 Perf Year295.65%
Cash/sh7.08 P/C7.07 EPS next 5Y- ROE-24.60% 52W Range12.10 - 62.83 Perf YTD18.88%
Dividend- P/FCF- EPS past 5Y- ROI-19.70% 52W High-20.34% Beta-
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low313.63% ATR2.33
Employees102 Current Ratio6.30 Sales Q/Q-80.40% Oper. Margin- RSI (14)49.45 Volatility3.22% 4.68%
OptionableYes Debt/Eq0.00 EPS Q/Q-145.20% Profit Margin- Rel Volume0.41 Prev Close49.60
ShortableYes LT Debt/Eq0.00 EarningsMar 12 AMC Payout- Avg Volume370.05K Price50.05
Recom1.60 SMA202.66% SMA50-3.68% SMA20020.45% Volume150,691 Change0.91%
Jan-18-18Resumed Credit Suisse Outperform $60
Dec-12-17Initiated JP Morgan Overweight $54
Sep-19-17Reiterated Credit Suisse Outperform $45 → $55
Dec-04-15Initiated Wells Fargo Outperform
Nov-23-15Initiated Wedbush Outperform $22
Nov-23-15Initiated Credit Suisse Outperform $18
Apr-09-18 08:10AM  New Research Coverage Highlights Alliance Resource Partners, MyoKardia, Pan American Silver, Stitch Fix, Codexis, and Chemical Financial Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Apr-04-18 08:30AM  MyoKardia Announces Appointment of Taylor C. Harris as Chief Financial Officer GlobeNewswire
Apr-02-18 08:30AM  MyoKardia Begins Dosing in Phase 2 MAVERICK-HCM Clinical Trial of Mavacamten in Symptomatic Non-obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
Mar-16-18 08:15AM  Recent Analysis Shows Clementia Pharmaceuticals, MyoKardia, Landec, Sapiens International Corporation N.V, AppFolio, and China Biologic Products Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Mar-09-18 09:50AM  Edited Transcript of MYOK earnings conference call or presentation 8-Mar-18 9:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 05:28PM  MyoKardia reports 4Q loss Associated Press
04:03PM  MyoKardia Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
04:02PM  MyoKardia Announces Positive Results from Low-Dose Cohort of Phase 2 PIONEER-HCM Study of Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy Patients GlobeNewswire
01:15PM  MyoKardia, Inc. to Host Earnings Call ACCESSWIRE
09:34AM  Earnings Preview For MyoKardia Benzinga
Mar-06-18 08:00AM  MyoKardia to Present at the Cowen and Company 38th Annual Health Care Conference GlobeNewswire
Mar-01-18 04:30PM  MyoKardia to Report Fourth Quarter and Full Year 2017 Financial Results on Thursday, March 8, 2018 GlobeNewswire
Feb-27-18 08:20AM  Todays Research Reports on Stocks to Watch: Endocyte and MyoKardia ACCESSWIRE -5.56%
Feb-14-18 04:30PM  MyoKardia to Present at the RBC Capital Markets 2018 Healthcare Conference GlobeNewswire +6.53%
08:30AM  MyoKardia Begins Patient Dosing in Phase 1b Clinical Study of MYK-491 in Dilated Cardiomyopathy Patients GlobeNewswire
Jan-19-18 08:30AM  MyoKardia Announces Appointment of Cynthia Ladd as General Counsel GlobeNewswire
Jan-16-18 03:50PM  Edited Transcript of MYOK earnings conference call or presentation 2-Nov-17 8:30pm GMT Thomson Reuters StreetEvents
Jan-10-18 12:08PM  4 Biotechs with Near Term Catalysts: G1 Therapeutics, Inc. (GTHX), Sierra Oncology Inc (SRRA), Myokardia Inc (MYOK), Jounce Therapeutics (JNCE) SmarterAnalyst
Jan-03-18 04:30PM  MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-26-17 11:51AM  ETFs with exposure to MyoKardia, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:21AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-11-17 07:25AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : December 11, 2017 Capital Cube
Nov-15-17 08:00AM  Preclinical Studies with MyoKardias Mavacamten Demonstrate Evidence of Reduced Contractility and Improved Left Ventricular Compliance GlobeNewswire
Nov-13-17 07:15PM  MyoKardia Presents Data from Study of Machine Learning Algorithm Intended to Identify Obstructive Hypertrophic Cardiomyopathy Using a Wearable Biosensor GlobeNewswire
Nov-08-17 09:44AM  MyoKardia, Inc. Value Analysis (NASDAQ:MYOK) : November 8, 2017 Capital Cube
Nov-07-17 12:48PM  Myokardia Inc (MYOK) Q3:17 Update At First Glance SmarterAnalyst
Nov-06-17 07:17AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : November 6, 2017 Capital Cube
Nov-02-17 05:54PM  MyoKardia reports 3Q loss Associated Press
04:02PM  MyoKardia Reports Third Quarter 2017 Financial Results and Operational Progress GlobeNewswire
Nov-01-17 08:00AM  MyoKardia Announces Presentations at 2017 American Heart Association Scientific Sessions GlobeNewswire
Oct-31-17 08:00AM  MyoKardia to Present at Two Upcoming Investor Conferences in November GlobeNewswire
Oct-26-17 08:00AM  MyoKardia to Announce Third Quarter 2017 Financial Results on Thursday, November 2, 2017 GlobeNewswire
Oct-12-17 08:24AM  MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : October 12, 2017 Capital Cube
Oct-10-17 11:39AM  ETFs with exposure to MyoKardia, Inc. : October 10, 2017 Capital Cube
Oct-09-17 09:51AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q2, 2017 By the Numbers : October 9, 2017 Capital Cube
Oct-02-17 10:50AM  Best Sector ETF of Q3 and its Top-Performing Stocks Zacks
Sep-27-17 07:30AM  MyoKardia Provides Update on MYK-491 Clinical Progress GlobeNewswire
Sep-25-17 07:01PM  Cramer's lightning round: Why I can't go down the path of... CNBC Videos -5.20%
06:48PM  Cramer's lightning round: Why I can't go down the path of US Steel CNBC
Sep-18-17 04:45PM  MyoKardia Unveils More Phase 2 Data on Heart Disease Treatment TheStreet.com
12:45PM  MyoKardia Presents Additional Positive Data from Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) at the Heart Failure Society of Americas 21st Annual Scientific Meeting GlobeNewswire
Aug-30-17 08:00AM  MyoKardia to Present at Two Upcoming Investor Conferences in September GlobeNewswire
Aug-16-17 08:58AM  MyoKardia (MYOK) Looks Good: Stock Adds 6.32% in Session Zacks +5.69%
Aug-14-17 11:14AM  MyoKardia Announces Closing of Public Offering of Common Stock Including Full Exercise of Option to Purchase Additional Shares GlobeNewswire
Aug-10-17 08:00AM  MyoKardia to Present at 2017 Wedbush PacGrow Healthcare Conference GlobeNewswire
Aug-09-17 07:30AM  [$$] Zinsli's Take: Biotech's Saviors Keep Up VCs' Hopes The Wall Street Journal
Aug-08-17 08:16PM  MyoKardia Announces Pricing of Public Offering of Common Stock GlobeNewswire +15.10%
04:21PM  Edited Transcript of MYOK earnings conference call or presentation 7-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
04:12PM  MyoKardia Inc. Is on the Rise Again Today -- Here's Why Motley Fool
Aug-07-17 11:59PM  MyoKardia reports 2Q loss Associated Press +83.38%
04:20PM  Why NxStage Medical, MyoKardia, and Rockwell Collins Jumped Today Motley Fool
04:01PM  MyoKardia Announces Proposed Public Offering of Common Stock GlobeNewswire
03:14PM  MyoKardia Shares Almost Double on Latest Clinical Data for Heart Disease Treatment TheStreet.com
12:25PM  Here's Why Myokardia Inc. Stock Shot Up Today Motley Fool
07:34AM  MyoKardia shares surge 32% on positive mid-stage trial results for heart muscle disease MarketWatch
07:19AM  MyoKardia Reports Second Quarter 2017 Financial Results and Operational Progress GlobeNewswire
07:00AM  MyoKardia Reports Positive Topline Results in Phase 2 PIONEER-HCM Study of Mavacamten (Formerly MYK-461) in Symptomatic, Obstructive Hypertrophic Cardiomyopathy GlobeNewswire
Jul-31-17 08:01AM  MyoKardia to Announce Second Quarter 2017 Financial Results and Host Conference Call on Monday, August 7, 2017 GlobeNewswire
Jul-24-17 05:30PM  ETFs with exposure to MyoKardia, Inc. : July 24, 2017 Capital Cube
Jul-21-17 08:37AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 21, 2017 Capital Cube
Jul-14-17 03:47PM  ETFs with exposure to MyoKardia, Inc. : July 14, 2017 Capital Cube
Jul-12-17 03:31PM  MyoKardia, Inc. Value Analysis (NASDAQ:MYOK) : July 12, 2017 Capital Cube
Jul-11-17 08:23AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : July 11, 2017 Capital Cube
Jun-28-17 09:01AM  MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : June 28, 2017 Capital Cube
Jun-15-17 02:42PM  ETFs with exposure to MyoKardia, Inc. : June 15, 2017 Capital Cube
Jun-09-17 09:21AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q1, 2017 By the Numbers : June 9, 2017 Capital Cube
Jun-02-17 08:39AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : June 2, 2017 Capital Cube
May-09-17 06:44PM  MyoKardia reports 1Q loss Associated Press
04:02PM  MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress GlobeNewswire
02:15PM  Investor Network: MyoKardia, Inc. to Host Earnings Call Accesswire
May-02-17 08:30AM  MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017 GlobeNewswire
Apr-26-17 04:21PM  MyoKardia, Inc. Value Analysis (NASDAQ:MYOK) : April 26, 2017 Capital Cube
Apr-25-17 08:58AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : April 25, 2017 Capital Cube
Apr-18-17 08:30AM  MyoKardia Appoints David Meeker, M.D., to Board of Directors GlobeNewswire
Apr-13-17 12:36PM  ETFs with exposure to MyoKardia, Inc. : April 13, 2017 Capital Cube
Apr-06-17 08:27AM  MyoKardia, Inc. breached its 50 day moving average in a Bearish Manner : MYOK-US : April 6, 2017 Capital Cube
Mar-23-17 12:13PM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 23, 2017 Capital Cube
10:11AM  MyoKardia, Inc. :MYOK-US: Earnings Analysis: 2016 By the Numbers : March 23, 2017
Mar-17-17 01:04PM  MYOKARDIA INC Financials
08:30AM  MyoKardia Appoints Kim Popovits and Wendy Yarno to Board of Directors GlobeNewswire
Mar-13-17 09:11AM  MYOKARDIA INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
08:40AM  MyoKardia reports 4Q loss Associated Press
08:30AM  MyoKardia Reports Fourth Quarter and Full Year 2016 Financial Results and Operational Progress GlobeNewswire
Mar-10-17 07:50AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : March 10, 2017 Capital Cube
Mar-06-17 07:17AM  MYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
Mar-02-17 07:00AM  7 Stocks Trending With Monster Volume TheStreet.com
Feb-28-17 08:30AM  MyoKardia to Present at Cowen and Company 37th Annual Health Care Conference GlobeNewswire
Feb-17-17 07:50AM  MyoKardia, Inc. breached its 50 day moving average in a Bullish Manner : MYOK-US : February 17, 2017 Capital Cube
Feb-02-17 08:30AM  First Subjects Dosed in Phase 1 Study of Dilated Cardiomyopathy Candidate MYK-491 GlobeNewswire
Feb-01-17 05:19PM  MYOKARDIA INC Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Stat +6.70%
08:30AM  MyoKardia Announces Appointment of June Lee, M.D., as Chief Operating Officer and Radhika Tripuraneni, M.D., as Vice President, Medical Affairs GlobeNewswire
Jan-03-17 08:41AM  MYOKARDIA INC Files SEC form 8-K, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
08:30AM  MyoKardia Announces Advancement to Next Phase of Global Collaboration with Sanofi GlobeNewswire
Dec-12-16 02:42PM  ETFs with exposure to MyoKardia, Inc. : December 12, 2016
Dec-09-16 03:21AM  Is Myokardia Inc (MYOK) A Good Stock To Buy? at Insider Monkey
Dec-08-16 08:00AM  MyoKardia to Present at 2016 BMO Capital Markets Healthcare Conference GlobeNewswire -5.23%
Dec-05-16 08:15AM  Blog Coverage MyoKardia Announced Receipt of Payment from Sanofi Accesswire
Dec-02-16 08:00AM  MyoKardia Announces Receipt of Milestone Payment from Sanofi for DCM Candidate MYK-491 GlobeNewswire
Dec-01-16 11:42AM  ETFs with exposure to MyoKardia, Inc. : December 1, 2016
08:00AM  MyoKardia Announces Appointment of Marc Semigran, M.D., as Chief Medical Officer GlobeNewswire
MyoKardia, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which has completed Phase II clinical trial that is designed to reduce left ventricular contractility to potentially alleviate the functional consequences and symptoms of hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression. The company also develops MYK-491, an orally-administered small molecule, which is in Phase I b clinical trial that is designed to restore normal contractility in the diseased dilated cardiomyopathy (DCM) heart. Its three preclinical programs include HCM-2 that is used to reduce cardiac muscle contractility to normal levels in HCM patients; DCM-2, which is used to enhance cardiac muscle contractility to normal levels in genetic DCM patients; and LUS-1 that is used to counteract a muscle disruption that results in impaired relaxation of the heart, a biomechanical defect found in specific HCM and genetic DCM patient subgroups, as well as in other less common heritable cardiomyopathies. The company has a strategic collaboration with Aventis Inc. for the research, development, and commercialization of pharmaceutical products to treat, prevent, and diagnose HCM and DCM, as well as additional indications. MyoKardia, Inc. was founded in 2012 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bauer JakeSee RemarksApr 11Option Exercise12.255,00061,25066,777Apr 12 08:32 PM
Bauer JakeSee RemarksApr 11Sale50.005,000250,00061,777Apr 12 08:32 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Option Exercise1.513,0004,52077,390Apr 05 07:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOApr 04Sale47.953,000143,86374,390Apr 05 07:48 PM
Bauer JakeSee RemarksMar 26Option Exercise9.081641,48961,941Mar 28 04:08 PM
Bauer JakeSee RemarksMar 26Sale50.951648,35661,777Mar 28 04:08 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 05Option Exercise1.513,0004,52077,390Mar 07 04:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOMar 05Sale61.073,000183,20574,390Mar 07 04:48 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 26Option Exercise1.515,0007,53479,390Feb 28 07:29 PM
Bauer JakeSee RemarksFeb 26Option Exercise9.085,10246,32666,879Feb 28 07:34 PM
Bauer JakeSee RemarksFeb 26Sale60.005,102306,12061,777Feb 28 07:34 PM
Lambing JosephSee RemarksFeb 26Sale60.002,300138,00093,546Feb 28 07:31 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 26Sale60.005,000300,00074,390Feb 28 07:29 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 05Option Exercise1.513,0004,52077,390Feb 07 06:37 PM
GIANAKAKOS ANASTASIOSPresident and CEOFeb 05Sale51.053,000153,13974,390Feb 07 06:37 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 12Option Exercise1.515,0007,534514,117Jan 16 06:47 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 12Sale50.005,000250,000509,117Jan 16 06:47 PM
Lambing JosephSee RemarksJan 12Sale50.005,000250,00095,846Jan 16 06:46 PM
Bauer JakeSee RemarksJan 09Sale45.005,000225,00056,777Jan 10 04:45 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 04Option Exercise1.513,0004,520512,117Jan 05 05:27 PM
GIANAKAKOS ANASTASIOSPresident and CEOJan 04Sale41.703,000125,103509,117Jan 05 05:27 PM
STARR KEVIN PDirectorJan 03Sale42.00816,32634,285,774680,272Jan 05 04:30 PM
Third Rock Ventures III, L.P.10% OwnerJan 03Sale42.00816,32634,285,774680,272Jan 05 04:30 PM
Bauer JakeSee RemarksJan 02Sale42.895,000214,46661,777Jan 03 08:06 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 21Option Exercise1.513,0004,520512,117Dec 26 04:46 PM
GIANAKAKOS ANASTASIOSPresident and CEODec 21Sale41.093,000123,268509,117Dec 26 04:46 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 06Option Exercise1.514,3006,479513,417Nov 08 06:04 PM
GIANAKAKOS ANASTASIOSPresident and CEONov 06Sale40.234,300172,990509,117Nov 08 06:04 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Option Exercise1.514,3006,479512,463Oct 06 06:49 PM
GIANAKAKOS ANASTASIOSPresident and CEOOct 04Sale40.864,300175,699508,163Oct 06 06:49 PM
STARR KEVIN PDirectorOct 03Sale40.2875,3133,033,57870,763Oct 04 04:00 PM
STARR KEVIN PDirectorSep 26Sale43.00400,00017,200,0006,885,104Sep 27 04:00 PM
Third Rock Ventures II, L.P.10% OwnerSep 26Sale43.00400,00017,200,0006,885,104Sep 27 04:01 PM
STARR KEVIN PDirectorSep 25Sale43.00201,4008,660,2007,285,104Sep 27 04:00 PM
Third Rock Ventures II, L.P.10% OwnerSep 25Sale43.00201,4008,660,2007,285,104Sep 27 04:01 PM
Third Rock Ventures II, L.P.10% OwnerSep 11Sale44.2520,000885,08057,651Sep 12 04:05 PM
STARR KEVIN PDirectorSep 08Sale41.01201,2508,252,4997,486,504Sep 12 04:05 PM
Third Rock Ventures II, L.P.10% OwnerSep 08Sale41.01201,2508,252,4997,486,504Sep 12 04:05 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 05Option Exercise1.514,3006,479512,463Sep 07 04:06 PM
GIANAKAKOS ANASTASIOSPresident and CEOSep 05Sale43.024,300185,004508,163Sep 07 04:06 PM
Lambing JosephSee RemarksAug 22Sale45.005,000225,00099,718Aug 24 04:05 PM
Lambing JosephSee RemarksAug 15Sale40.005,000200,000104,718Aug 16 04:32 PM
YARNO WENDY LDirectorAug 14Buy35.501,40849,9841,408Aug 16 04:33 PM
Sanofi10% OwnerAug 14Buy35.50350,00012,425,0004,018,899Aug 16 07:31 AM
Lambing JosephSee RemarksAug 08Sale35.005,000175,000109,718Aug 09 05:16 PM
Lambing JosephSee RemarksAug 07Sale27.5010,000275,000114,718Aug 09 05:16 PM
Bauer JakeSee RemarksAug 07Sale28.3315,000425,00065,545Aug 09 05:15 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 04Option Exercise1.514,3006,479512,463Aug 04 09:31 PM
GIANAKAKOS ANASTASIOSPresident and CEOAug 04Sale16.624,30071,465508,163Aug 04 09:31 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 25Option Exercise1.5131,85048,094541,151Jul 27 05:11 PM
GIANAKAKOS ANASTASIOSPresident and CEOJul 25Sale15.0032,988494,902508,163Jul 27 05:11 PM
Bauer JakeSee RemarksJul 25Sale15.024,33365,06080,545Jul 27 05:11 PM